Ethics: Investigators' Interests: What Should Trial Participants Be Told?
Romain, Paul L.
Nature Reviews. Rheumatology 2010 February; 6(2): 70-71
Minimizing the potential adverse effects of clinical investigators' financial conflicts of interest involves, in part, determining how much of an investigator's "business" should be disclosed to participants in research studies. What should be disclosed and why? How will we know if disclosure matters?
Showing items related by title, author, creator and subject.
Post-Trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study Pace, Christine; Grady, Christine; Wendler, David; Bebchuk, Judith D.; Tavel, Jorge A.; McNay, Laura A.; Forster, Heidi P.; Killen, Jack; Emanuel, Ezekiel J. (Espirit Group, 2006-09)
Ferriman, Annabel (1999-03-27)
Wendler, David; Grady, Christine (2008-05)To give valid informed consent to participate in clinical research, potential participants should understand the risks, potential benefits, procedures, and alternatives. Potential participants also should understand that ...